ESMO 2024

Hypofractionation in early breast cancer

Therapy de-escalation and balancing individualized therapy management in early breast cancer patients

New updates from the innovative I-SPY program

Escalation, De-escalation and management of therapy: how to identify the best treatment option for our patients?

4-year update of Riboclib in EBC - can we avoid chemo?

Survival data from WSG-TP-II

Registry data from France - no break in endocrine therapy in young patients

Endocrine therapy in triple-positive premenopausal patients

Survival benefit reported with Pembro

Physical exercise and oncological outcome

Overall survival advantage for Pembrolizumab in early TNBC

Compliance is everything

Evaluation of the patient collective under 40 years

Update on NATALEE in young patients

Ribociclib in younger patients

4-year landmark data

Update on NATALEE in young patients

Physical exercise and oncological outcome

T-DXD for everyone - what is the minimal threshold for HER2: How to sequence therapies?

De-Escalation in the metastatic setting

No benefit of Akt-inhibition in mTNBC

Keep the patients trained!

Highlights of ESMO 2024

Brain imaging screening in MBC patients

TILs and overall survival in the shortHER trial

PIK3CA is not a vaild pathway in triple-negative breast cancer

Brain imaging screening in MBC patients

New approaches to treat 1L patients mTNBC

Akt-inhibition works with HR+ but not with mTNBC

PIK3CA is not a vaild pathway in triple-negative breast cancer

TILs e sopravvivenza nello studio shortHER

Punti salienti di ESMO 2024

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

Promosing results for the new ADC in HR+ - negative results for pAKT inhibitors in mTNBC: we have to better understand the biology.

New first choice treatment for patients with brain metastases?

Her3-Dxd - new application area for ADCs

T-Dxd in BrainMets

HER3- DXd in the ICARUS Breast-01 study

Endocrine-based therapy in combination with dual blockade

Primary systematic treatment of active brain metastases

Outstanding efficacy of T-Dxd in CNS meastases

High sensitivity testing as outcome predictor for T-DXD in mBC

ctDNA data and clinical efficacy of SG

Study impression in HR+/HER2- mBC progressing after two lines of therapy

Efficacy of T-Dxd in patients with brain metastasis

Soon no chemotherapy for triplenegative mBC

Optimization treatment with ADCs in endocrine therapy

T-Dxd in patients with and without brain metastases

Primary results of DB-12

Impression d'étude dans le cancer du sein métastatique HR+/HER2- progressant après deux lignes de traitement

Impressione dello studio nel carcinoma mammario metastatico HR+/HER2- in progressione dopo due linee di terapia

Optimization treatment with ADCs in endocrine therapy

Risultati primari dello studio DB-12

Endocrine resistance to CDK4/6 inhibitors

Screening for brain metastases – what do doctors and patients think about it?

CTCs as surrogate markers for endocrine therapy

Niraparib in ovarian cancer without survival benefit

Overview on the perioperative treatment landscape

The importance of markers for patient management

Perioperative IO Therapy - adjuvant necessary?

ctDNA - a promising new biomarker in early lung cancer

Significant CNS protection by osimertinib

Should we move away from adjuvant immunotherapy?

Neoadjuvant vs. Perioperative

BR31: The first negative adjuvant study in resected NSCLC

Negative adjuvant CPI trial

Durvalumab did not meet primary endpoint in CCTG BR.31 trial

Getting rid of it will save your life!

BR31: La première étude d’immunothérapie adjuvante négative dans les CBNPC réséqués

Should we move away from adjuvant immunotherapy?

Eliminarlo potrebbe salvarti la vita

Durvalumab non ha raggiunto l'endpoint primario nello studio CCTG BR.31

Update on genetic alterations - ALK / ROS / KRAS / BRAF

Pieces of evidence in the EGFR domain

New 1st line treatment opportunities in advanced stage NSCLC

Survival Data with Amivantamab for EGFR Alteration

Patterns of resistance in MARIPOSA trial

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1 > 50 %

NVL-520 for ROS alteration - already best in class?

The next generation of ROS inhibitors

NVL-655: a promising new ALK inhibitor

Quality of life with Telisotuzumab in LUMINOSITY

Two sometimes may be better than one!

RELATIVITY-104: efficacy of anti immunotherapy

MARIPOSA - lower rate of MET amplification and EGFR resistance mutation

NVALT: 1st attempt to reduce dose of pembrolizumab and limit the financial burden

Sustained OS at 2nd interim analysis in MARIPOSA-2

Early mechanisms of resistance from MARIPOSA

Bispecific antibodies better than ADCs?

The next generation of ALK inhibitors

1st line encorafenib + binimetinib: combination is very active but PFS very different

Optimizing the dose of immunotherapy

Second interim analysis of MARIPOSA-2

Half of the dose - same activity: provocative findings from NVALT-30

Adding anti-LAG-3 doesn't seem to being worth it

4th generation with ALK-alterations

Optimizing the dose of immunotherapy

Quality of life with Telisotuzumab in LUMINOSITY

NVALT: Première tentative pour réduire la dose de pembrolizumab dans les CBNPC de stade IV et réduire le cout du traitement

Patterns of resistance in MARIPOSA trial

2 a volte sono meglio di uno

CBNPC muté BRAF en 1ère ligne : encorafenib + binimetinib : association très active mais la SSP très différente selon les études

RELATIVITY-104: efficacy of anti immunotherapy

Second interim analysis of MARIPOSA-2

Aggiungere l'anti-LAG-3 non sembra valerne la pena

New data on SCLC and mesothelioma

New standard of care in LS-SCLC

Subset analysis from ADRIATIC

Neuer Behandlungsstandard beim LS-SCLC

Is the radiologist redundant in mesothelioma RECIST measurements

Response assessment in mesothelioma - can AI help?

Is the radiologist redundant in mesothelioma RECIST measurements

Practice changing- Big Revival - Or just a Splish? Don't forget the bone protection!

Doublet therapy in prostate cancer: Practice changing or rather practice informing?

IO in mCRPC: Let's move on to the next substance?!

We come in PEACE

Not a Patch on ADT?

Darolutamide in mHSPC

Molecular analysis from PEACE-1

Did CONTACT make any contact?

New hormone therapy for mCRPC

Upfronts in personal

Metformin in mHSPC

Radium and enzalutamide in mCRPC - final results

PSMA-radioligand - the first study of its kind

Immunotherapy for prostate cancer

LuPSMA moves UpFront

Radium223 Prior to Docetaxel Improves Quality of Life in Bone-Dominant mCRPC: Findings from the RAPSON Phase 2 Trial

New PSMA-ligand

Radium-223 an option again?

Was it a splash or was it a splish?

Molecular analysis from PEACE-1

Radium and enzalutamide in mCRPC - final results

PSMA-radioligand - the first study of its kind

New PSMA-ligand

IO after IO – is there a role for sequential immunotherapy in RCC?

Where is the right place for HIF inhibitors in advanced RCC therapy?

Establishing ICI as standard of care in RCC

Microbiome transplantation in RCC – how to tailor this therapy for our patients

Glycoproteins as Predictive Biomarkers for Nivolumab Plus Cabozantinib Response in Advanced Renal Cell Carcinoma

Immunotherapy for nccRCC

Opening a new way of treatment in MIBC

HIF-2a inhibitors are on their way

The role of sequencing therapy in RCC

IO therapy is standard for nccRCC

Stool transplantation is the shit

New SOC for non-cc-RCC?

SUNNIFORECAST - rain or shine?

Sequencing checkpoint inhibitors - the story is over

mRCC ≥ 1L? News on intensification?

FMT in a novel setting

TKI monotherapy remains standard in 2ndL

Treating nccRCC - Nivo/Ipi as a new potential option

Updated survival results

Ipi-Nivo in nccRCC

CPI - modification / prediction - fact or fantasy?

My view on SUNNIFORECAST

Se abre una nueva vía de tratamiento en el cáncer de vejiga con invasión muscular

Tratamiento del nccRCC - Nivo/Ipi como nueva opción potencial

Sequencing checkpoint inhibitors - the story is over

Chemo + IO in the perioperative setting - new standard of care

Encouraging data - but we need more data!

Biomarkers in Bladder cancer - the road to individualized therapy

A new way to give chemo for patients who are ineligible for neoadj therapy

New standard: perioperative MIBC-NIAGARA

EV + Pembro is broadly effective

Practice changing new data in Bladder cancer at ESMO24

NIAGARA sets new standard

Pretzel therapy for superficial UC

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality of Life in Metastatic Urothelial Carcinoma

Value of ctDNA

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

mUC - new ADC's?

Is intravesical therapy as easy as baking a pretzel?

New data on ADCs in bladder cancer

Nuevos datos sobre las ADC en el cáncer de vejiga

Practice changing new data in Bladder cancer at ESMO24

A new way to give chemo for patients who are ineligible for neoadj therapy